The timing of chemotherapy given to patients with small cell lung cancer (SCLC) does not have a statistically significant effect on OS, said Faruk Tas and colleagues, despite previous research showing that a delay of treatment may lead to adverse patient outcomes.
Advertisement
Longer follow-up results of the RUBY-3 trial found povetacicept is well-tolerated and shows promise for IgAN treatment.
Stuart Orkin, MD, has been named as one of Time’s 100 Most Influential People of 2024 for his work in hemoglobin research.
Researchers uncovered clinical and economic of the Kidney BEAM physical activity digital health intervention for CKD.
A study assessed deucravacitinib in patients with active psoriatic arthritis compared with placebo.
Positive trial results and FDA approvals have changed the standard of care for NSCLC.
A study compared the long-term survival outcomes of endoscopic and surgical treatment for GISTs ranging from 5 to 10 cm.
A study examined the risk factors, prevalence, and impact of pruritus associated with CKD in hemodialysis patients.
Researchers found that sparsentan had a clinically meaningful benefit on long-term kidney preservation versus irbesartan.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
A study compared the long-term survival outcomes of endoscopic and surgical treatment for GISTs ranging from 5 to 10 cm.
Researchers also found statistical significance for the TBR SULpeak of the primary and liver lesions.
Atezolizumab/bevacizumab and lenvatinib have both shown efficacy as first-line treatments for hepatocellular carcinoma.
A personalized therapeutic cancer vaccine may increase patient response to PD-1 inhibitors.
Drs. White and Berman consider how the post hoc analysis of CROSSFIRE elucidates the benefit of ablative therapy with IO.
Drs. White and Berman share insights gained from the CROSSFIRE trial comparing IRE with SBRT in advanced pancreatic cancer.
The Latest From Heme Today
Stuart Orkin, MD, has been named as one of Time’s 100 Most Influential People of 2024 for his work in hemoglobin research.
The study compared health care resource use and costs of pediatric patients with SCD compared with matched controls.
Intravenous iron was safe and effective in pediatric patients with iron deficiency anemia and inflammatory bowel disease.
Delaying treatment for SAA until genetic testing for IBMFS may be detrimental in patients with negative workup and history.
Dr. Ansong-Ansongton shared what National Minority Health Month and Celebrate Diversity Month mean to him at ASPHO 2024.
Dr. Ansong-Ansongton described data on the impact of abnormal mitochondrial retention and cold in red blood cells in SCD.
